- Home
- GALT vs CERT Comparison
GALT vs CERT Comparison
Compare GALT & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | CERT |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.0M | 1.2B |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GALT | CERT |
|---|---|---|
| Price | $3.76 | $9.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.34 |
| AVG Volume (30 Days) | 248.5K | ★ 2.0M |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 36.84 | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $2.03 | $4.45 |
| 52 Week High | $7.13 | $13.88 |
Technical Indicators
Market Signals| Indicator | GALT | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 67.06 |
| Support Level | $3.56 | $9.06 |
| Resistance Level | $4.30 | $10.04 |
| Average True Range (ATR) | 0.19 | 0.39 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 71.97 | 96.76 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.